Literatuur

Referenties

  1. Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 2014;384:319-28.
  2. Sorafenib bij het lokaal gevorderd of gemetastaseerd jodium-refractair gedifferentieerd schildkliercarcinoom. advies commissie BOM november 2014.
  3. Final overall survival analysis of patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) treated with sorafenib in the phase 3 DECISION trial: An exploratory crossover adjustment analyses. abstract 953PD. Annals of Oncology 27 (Supplement 6): vi328–vi350, 2016.
  4. Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. The New England journal of medicine 2015;372:621-30.
  5. Lenvatinib bij het lokaal gevorderd of gemetastaseerd jodium-refractair gedifferentieerd schildkliercarcinoom. Advies commissie BOM juni 2016.
  6. Drilon A, Laetsch TW, Kummar S, et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. The New England journal of medicine 2018;378:731-9.
  7. Libretto-001 study. unpublished.
  8. Wells SA, Jr., Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30:134-41.
  9. Vandetanib bij het lokaal gevorderd of gemetastaseerd medullair schildkliercarcinoom. advies commissie BOM maart 2013.
  10. Elisei R, Schlumberger MJ, Muller SP, et al. Cabozantinib in progressive medullary thyroid cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31:3639-46.
  11. Cabozantinib bij het lokaal gevorderd of gemetastaseerd medullair schildkliercarcinoom. Advies commissie BOM april 2015.
  12. Schlumberger M, Elisei R, Muller S, et al. Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma. Annals of oncology : official journal of the European Society for Medical Oncology 2017;28:2813-9.
  13. Subbiah V, Kreitman RJ, Wainberg ZA, et al. Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018;36:7-13.
  14. Smallridge RC, Ain KB, Asa SL, et al. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid 2012;22:1104-39.
ga naar hoofdinhoud
Informatie voor zorgprofessionals Medische Oncologie Tumortypes Schildkliercarcinoom

Schildkliercarcinoom subtypes

lees meer

Schildkliercarcinoom subtypes

Incidentie: 600 patiënten per jaar.                                                                                                     

Subtypes:

  • Gedifferentieerd (tumormarker = thyreoglobuline)
    • NIFTP: non-invasive follicular thyroid neoplasm with papillary-like nuclear features,
    • Papillair,
    • Folliculair,
    • Hürthle cell,
    • Slecht gedifferentieerd.
  • Medullair (tumormarker = calcitonine en CEA),
    • 20-30% erfelijk, m.n. MEN2 syndroom.
  • Anaplastisch: ongedifferentieerd schildkliercarcinoom.

Tumorsoorten

Gedifferentieerd schildklier­carcinoom

lees meer

Medullair schildklier­carcinoom

lees meer

Anaplastisch schildklier­carcinoom

lees meer

Literatuur

lees meer

Filter

Studies

DO2.22.01

Solide tumoren, fase I, MET, MET kinase inhibitor

Debio 0123

Solide tumoren, fase I, 2e lijn, selectieve WEE1 remmer (+carboplatine)

DRUP

Solide tumoren, ‘actionable’ moleculaire target

DRUG access

Solide tumoren, EMA geregistreerde middelen